Clinical Significance of Platelet-Derived Growth Factor-C Expression in Colorectal Cancer

Shinichi Yamauchi, Satoru Iida, Megumi Ishiguro, Toshiaki Ishikawa, Hiroyuki Uetake, Kenichi Sugihara

Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Translational Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

DOI: 10.4236/jct.2014.51002                

Abstract

Platelet-derived growth factors (PDGFs) are known to be associated with tumor growth and angiogenesis through their activation of the receptor tyrosine kinases, PDGF receptors alpha and beta. Several studies revealed the participation of the PDGF family in colorectal cancer (CRC). However, the role of platelet derived growth factor-C (PDGFC) in CRC is less well studied. This study aimed to determine the correlation between PDGFC expression and the prognosis of patients with CRCs. Tumor samples were obtained from patients with CRC who underwent surgical resection between 2002 and 2006. The mRNA expression of PDGFC was investigated by quantitative reverse transcription-polymerase chain reaction in 85 patients with stage I-IV CRC. PDGFC protein expression was analyzed by immunohistochemistry, and the relationship between PDGFC protein expression and clinicopathologic features was investigated in 245 patients with stage I-III CRC. PDGFC mRNA expression in cancer tissues was significantly higher in patients with distant metastases than in those without metastases (P = 0.016). PDGFC protein overexpression was associated with significantly worse overall and relapse-free survival (P < 0.0001 and P < 0.0001, respectively). Moreover, PDGFC protein overexpression was an independent risk factor for CRC recurrence (relative risk = 3.395, 95% confidence interval = 1.895 - 6.081, P < 0.001). In the present study, PDGFC overexpression appeared to be predictive of recurrence and poor prognosis in patients with CRC.

Keywords

Platelet-Derived Growth Factor-C; Colorectal Cancer; Prognosis, mRNA Expression; Immunohistochemistry

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. Siegel, D. Naishadham and A. Jemal, “Cancer Statistics, 2012,” CA: A Cancer Journal for Clinicians, Vol. 62, No. 1, 2012, pp. 10-29. http://dx.doi.org/10.3322/caac.20138
[2]	H. Kobayashi, H. Mochizuki, T. K. Sugihara, Morita, K. Kotake, T. Teramoto, et al., “Characteristics of Recurrence and Surveillance Tools after Curative Resection for Colorectal Cancer: A Multicenter Study,” Surgery, Vol. 141, No. 1, 2007, pp. 67-75. http://dx.doi.org/10.1016/j.surg.2006.07.020
[3]	J. Weitz, M. Koch, J. Debus, T. Hohler, P. R. Galle and M. W. Buchler, “Colorectal Cancer,” Lancet, Vol. 365, No. 9454, 2005, pp. 153-165. http://dx.doi.org/10.1016/S0140-6736(05)17706-X
[4]	A. B. Benson III, D. Schrag, M. R. Somerfield, A. M. Cohen, A. T. Figueredo, P. J. Flynn, et al., “American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer,” Journal of Clinical Oncology, Vol. 22, No. 16, 2004, pp. 3408-3419. http://dx.doi.org/10.1200/JCO.2004.05.063
[5]	J. Merla and S. Goel, “Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review,” Chemotherapy Research and Practice, Vol. 1, 2012, pp. 225-235.
[6]	M. Inanc, O. Er, H. Karaca, V. Berk, M. Ozkan, R. Saraymen, et al., “Prognostic Value of Tumor Growth Factor Levels during Chemotherapy in Patients with Metastatic Colorectal Cancer,” Medical Oncology, Vol. 29, No. 5, 2012, pp. 3119-3124. http://dx.doi.org/10.1007/s12032-012-0250-8
[7]	M. Skobe and N. E. Fusenig, “Tumorigenic Conversion of Immortal Human Keratinocytes through Stromal Cell Activation,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, No. 3, 1998, pp. 1050-1055. http://www.pnas.org/content/95/3/1050.full http://dx.doi.org/10.1073/pnas.95.3.1050
[8]	K. Forsberg, I. Valyi-Nagy, C. H. Heldin, M. Herlyn and B. Westermark, “Platelet-Derived Growth Factor (PDGF) in Oncogenesis: Development of a Vascular Connective Tissue Stroma in Xenotransplanted Human Melanoma Producing PDGF-BB,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, 1993, pp. 393-397. http://www.pnas.org/content/90/2/393.long http://dx.doi.org/10.1073/pnas.90.2.393
[9]	Z. M. Shao, M. Nguyen and S. H. Barsky, “Human Breast Carcinoma Desmoplasia Is PDGF Initiated,” Oncogene, Vol. 19, No. 38, 2000, pp. 4337-4345. http://dx.doi.org/10.1038/sj.onc.1203785
[10]	M. L. Tejada, L. L. Yu, J. Y. Dong, K. Jung, G. Meng, F. V. Peale, et al., “Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor Alpha Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma,” Clinical Cancer Research, Vol. 12, 2006, pp. 2676-2688. http://dx.doi.org/10.1158/1078-0432.CCR-05-1770
[11]	D. G. Gilbertson, M. E. Duff, J. W. West, J. D. Kelly, P. O. Sheppard, P. D. Hofstrand, et al., “Platelet-Derived Growth Factor C (PDGF-C), a Novel Growth Factor That Binds to PDGF Alpha and Beta Receptor,” Journal of Biological Chemistry, Vol. 276, 2001, pp. 27406-27414. http://dx.doi.org/10. 1074/jbc.M101056200
[12]	X. Li, A. Pontén, K. Aase, L. Karlsson, A. Abramsson, M. Uutela, et al., “PDGF-C Is a New Protease-Activated Ligand for the PDGF Alpha-Receptor,” Nature Cell Biology, Vol. 2, 2000, pp. 302-309. http://dx.doi.org/10.1038/35010579
[13]	J. S. Campbell, S. D. Hughes, D. G. Gilbertson, T. E. Palmer, M. S. Holdren, A. C. Haran, et al., “Platelet-Derived Growth Factor C Induces Liver Fibrosis, Steatosis, and Hepatocellular Carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 9, 2005, pp. 3389-3394. http://dx.doi.org/10.1073/pnas.0409722102
[14]	E. Borkham-Kamphorst, E. Kovalenko, C. R. C. van Roeyen, N. Gassler, M. Bomble, T. Ostendorf, et al., “Platelet-Derived Growth Factor Isoform Expression in Carbon Tetrachloride-Induced Chronic Liver Injury,” Laboratory Investigation, Vol. 88, No. 10, 2008, pp. 1090-1100.
[15]	C. Anderberg, H. Li, L. Fredriksson, J. Andrae, C. Betsholtz, X. R. Li, et al., “Paracrine Signaling by Platelet-Derived Growth Factor-CC Promotes Tumor Growth by Recruitment of Cancer-Associated Fibroblasts,” Cancer Research, Vol. 69, 2009, pp. 369-378. http://dx.doi.org/10.1158/0008-5472.CAN-08-2724
[16]	T. Maass, F. R. Thieringer, A. Mann, T. Longerich, P. Schirmacher, D. Strand, et al., “Liver Specific Overexpression of Plateletderived Growth Factor-B Accelerates liver Cancer Development in Chemically Induced Liver Carcinogenesis,” International Journal of Cancer, Vol. 128, No. 6, 2010, pp. 1259-1268. http://dx.doi.org/10.1002/ijc.25469
[17]	X. Li, A. Pontén, K. Aase, L. Karlsson, A. Abramsson, M. Uutela, et al., “PDGF-C Is a New Protease-Activated Ligand for the PDGF Alpha-Receptor,” Nature Cell Biology, Vol. 2, 2000, pp. 302-309. http://dx.doi.org/10.1038/35010579
[18]	H. Ding, X. Wu, H. Bostr?m, I. Kim, N. Wong, B. Tsoi, et al., “A Specific Requirement for PDGF-C in Palate Formation and PDGFR-Alpha Signaling,” Nature Genetics, Vol. 36, 2004, pp. 1111-1116. http://dx.doi.org/10.1038/ng1415
[19]	A. T. Grazul-Bilska, M. L. Johnson, J. J. Bilski, D. A. Redmer, L. P. Reynolds, and A. Abdullah and K. M. Abdullah, “Wound Healing: The Role of Growth Factors,” Drugs Today (Barc), Vol. 39, No. 10, 2003, pp. 787-800. http://dx.doi.org/10.1358/dot.2003.39.10.799472
[20]	L. Fang, Y. Yan, L. G. Komuves, S. Yonkovich, C. M. Sullivan, B. Stringer, et al., “PDGF C Is a Selective Alpha Platelet-Derived Growth Factor Receptor Agonist That Is Highly Expressed in Platelet Alpha Granules and Vascular Smooth Muscle,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 24, 2004, pp. 787-792. http://dx.doi.org/10.1161/01.ATV.0000120785.82268.8b
[21]	X. Li, M. Tjwa, L. Moons, P. Fons, A. Noel, A. Ny, et al., “Revascularization of Ischemic Tissues by PDGF-CC via Effects on Endothelial Cells and Their Progenitors,” The Journal of Clinical Investigation, Vol. 115, No. 1, 2005, pp. 118-127.
[22]	M. Jinnin, H. Ihn, Y. Mimura, Y. Asano, K. Yamane and K. Tamaki, “Regulation of Fibrogenic/Fibrolytic Genes by Platelet-Derived Growth Factor C, a Novel Growth Factor, in Human Dermal Fibroblasts,” Journal of Cellular Physiology, Vol. 202, No. 2, 2005, pp. 510-517. http://dx.doi.org/10.1002/jcp. 20154
[23]	R. Cao, E. Brakenhielm, X. Li, K. Pietras, J. Widenfalk, A. Ostman, et al., “Angiogenesis Stimulated by PDGFCC, a Novel Member in the PDGF Family, Involves Activation of PDGFR-Alphaalpha and -Alphabeta Receptors,” The Journal of Federation of American Societies for Experimental Biology, Vol. 16, No. 12, 2002, pp. 1575-1583. http://dx.doi.org/10.1096/fj.02-0319com
[24]	F. Eitner, T. Ostendorf, C. Van Roeyen, M. Kitahara, X. Li, K. Aase, et al., “Expression of a Novel PDGF Isoform, PDGF-C, in Normal and Diseased Rat Kidney,” Journal of the American Society of Nephrology, Vol. 13, No. 4, 2002, pp. 910-917. http://www.ncbi.nlm.nih.gov/pubmed/11912250
[25]	S. Taneda, K. L. Hudkins, S. Topouzis, D. G. Gilbertson, V. Ophascharoensuk, L. Truong, et al., “Obstructive Uropathy in Mice and Humans: Potential Role for PDGF-D in the Progression of Tubulointerstitial Injury,” Journal of the American Society of Nephrology, Vol. 14, No. 10, 2003, pp. 2544-2555. http://www.ncbi.nlm.nih.gov/pubmed/14514732 http://dx.doi.org/10.1097/01.ASN.000 0089828.73014.C8
[26]	N. A. Lokker, C. M. Sullivan, S. J. Hollenbach, M. A. Israel and N. A. Giese, “Platelet-Derived Growth Factor (PDGF) Autocrine Signaling Regulates Survival and Mitogenic Pathways in Glioblastoma Cells: Evidence That the Novel PDGF-C and PDGF-D Ligands May Play a Role in the Development of Brain Tumors,” Cancer Research, Vol. 62, No. 13, 2002, pp. 3729-3735. http://www.ncbi.nlm.nih.gov/ pubmed/12097282
[27]	J. Andrae, C. Molander, A. Smits, K. Funa and M. Nister, “Platelet-Derived Growth Factor-B and -C and Active Alpha-Receptors in Medulloblastoma Cells,” Biochemical and Biophysical Research Communications, Vol. 296, No. 3, 2002, pp. 604-611. http://dx.doi.org/10.1016/S0006-291X(02) 00917-8
[28]	T. Rosenmuller, K. Rydh and E. Nanberg, “Role of Phosphoinositide 3OH-Kinase in Autocrine Transformation by PDGF-BB,” Journal of Cellular Physiology, Vol. 188, 2001, pp. 369-382. http://dx.doi.org/10.1002/jcp.1126
[29]	R. F. Doolittle, M. W. Hunkapiller, L. E. Hood, S. G. Devare, K. C. Robbins, S. A. Aaronson, et al., “Simian Sarcoma Virus Onc Gene, v-Sis, Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth Factor,” Science, Vol. 221, No. 4607, 1983, pp. 275-277. http://dx.doi.org/10. 1126/science.6304883
[30]	S. Ekman, E. R. Thuresson, C. H. Heldin and L. Ronnstrand, “Increased Mitogenicity of an Alphabeta Heterodimeric PDGF Receptor Complex Correlates with Lack of RasGAP Binding,” Oncogene, Vol. 18, No. 15, 1999, pp. 2481-2488. http://dx.doi.org/10.1038/sj.onc.1202606
[31]	J. P. Zwerner and W. A. May, “Dominant Negative PDGF-C Inhibits Growth of Ewing Family Tumor Cell Lines,” Oncogene, Vol. 21, No. 24, 2002, pp. 3847-3854. http://dx.doi.org/10.1038/sj.onc.1205486
[32]	H. Li, L. Fredriksson, X. Li and U. Eriksson, “PDGF-D Is a Potent Transforming and Angiogenic Growth Factor,” Oncogene, Vol. 22, 2003, pp. 1501-1510. http://dx.doi.org/10.1038/sj.onc.1206223
[33]	X. Li and U. Eriksson, “Novel PDGF Family Members: PDGF-C and PDGF-D,” Cytokine & Growth Factor Reviews, Vol. 14, No. 2, 2003, pp. 91-98. http://dx.doi.org/10.1016/S1359-6101(02)00090-4
[34]	U. McDermott, R. Y. Ames, A. J. Iafrate, S. Maheswaran, H. Stubbs, P. Greninger, et al., “Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-Alpha Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors,” Cancer Research, Vol. 69, 2009, pp. 3937-3946. http://dx.doi.org/10.1158/0008-5472.CAN-08-4327
[35]	E. C. Johnstone and D. J. Kerr, “What Is the Role and Impact of Molecular Markers on Treatment Decisions in the Adjuvant Setting of Colorectal Cancer?” Annals of Oncology, Vol. 19, Suppl. 7, 2008, pp. vii184-vii186. http://dx.doi.org/10.1093/annonc/mdn455
[36]	T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, et al., “Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer,” The New England Journal of Medicine, Vol. 350, 2004, pp. 2343-2351. http://dx.doi.org/10.1056/NEJMoa032709
[37]	S. Aballéa, J. V. Chancellor, M. Raikou, M. F. Drummond, M. C. Weinstein, S. Jourdan, et al., “Cost-Effectiveness Analysis of Oxaliplatin Compared with 5-Fluorouracil/Leucovorin in Adjuvant Treatment of Stage III Colon Cancer in the US,” Cancer, Vol. 109, No. 6, 2007, pp. 1082-1089. http://dx.doi.org/ 10.1002/cncr.22512
[38]	B. M. Wolpin and R. J. Mayer, “Systemic Treatment of Colorectal Cancer,” Gastroenterology, Vol. 134, No. 5, 2008, pp. 1296-1310. http://dx.doi.org/10.1053/j.gastro.2008.02.098
[39]	H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, et al., “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” The New England Journal of Medicine, Vol. 350, 2004, pp. 2335-2342. http://dx.doi.org/10.1056/NEJMoa032691